DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years
DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years
[Geneva - 8 August 2017] The Drugs for Neglected Diseases initiative (DNDi) announced today the appointment of Dr Marie-Paule Kieny as the new Chair of the Board of Directors. Dr Kieny, a former World Health Organization (WHO) Assistant Director-General, brings more than four decades of experience in public health and innovation to DNDi’s work in developing new treatments for neglected patients. Until July 2017, Dr Kieny led WHO’s Health Systems and Innovation cluster. During her career at WHO, she also led its Innovation, Information, Evidence and Research cluster, directed the WHO Initiative for Vaccine Research and led the organization’s activities on Ebola and Zika research, as well as the preparation of an R&D Blueprint to accelerate global preparedness for future pandemics. Before joining WHO in 2001, Dr Kieny was Director of Research at the Institute of Virology, Institut national de la Santé et de la Recherche médicale in Paris (INSERM) and Assistant Scientific Director of French biopharmaceutical company Transgene SA.
DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years
Antibiotic-resistant gonorrhoea on the rise; need for new drugs
Antibiotic-resistant gonorrhoea on the rise; need for new drugs
[Geneva - 7 July 2017] Joint WHO and GARDP/DNDi News Release: Data from 77 countries show that antibiotic resistance is making gonorrhoea - a common sexually-transmitted infection—much harder, and sometimes impossible, to treat. [Français]
Antibiotic-resistant gonorrhoea on the rise; need for new drugs
Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to develop a new treatment for drug-resistant gonorrhea
Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to develop a new treatment for drug-resistant gonorrhea
[Boston, Geneva - 6 July 2017] First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea. [Deutsch] [Français] [Português]
Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to develop a new treatment for drug-resistant gonorrhea
Clinical trial for a better treatment for mycetoma starts in Sudan
Clinical trial for a better treatment for mycetoma starts in Sudan
[Khartoum, Sudan – 19 June 2017] First ever double-blind study for disease so neglected that it only recently was added to WHO list of neglected tropical diseases The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre (MRC) in Khartoum, Sudan.
Clinical trial for a better treatment for mycetoma starts in Sudan
See all news

Scientific Articles

See all scientific articles

Events

  • IAS 2017

    9th IAS Conference on HIV Science

    July 23-26, 2017 Paris, France Isabelle Andrieux-Meyer, Paediatric HIV/HCV Team Leader at DNDi, presented on DNDi's work on HCV.
  • MedTrop 2017

    Congress of the Brazilian Society of Tropical Medicine

    August 27-30, 2017 Mato Grosso, Cuiabá, Brazil DNDi are participating in the 53rd Congress of the Brazilian Society of Tropical Medicine and in ChagasLeish 2017, a meeting that will be held within the congress.
  • XXV Brazilian Parasitology Congress September 3-6, 2017 Búzios, Rio de Janeiro, Brazil DNDi will present an abstract on LOLA hit-to-lead results.
  • 19th Cambridge Medicinal Chemistry Symposium September 10-13, 2017 Cambridge, UK Charles Mowbray, Head of Discovery, DNDi, will participate in the event.
  • Basel Life 2017 September 11-14, 2017 Basel, Switzerland Bernard Pécoul, Executive Director, DNDi, will speak at the event.
See all events